Abstract
Methylation of 5′ CpG islands in promoter and upstream coding regions has been identified as a mechanism for transcriptional inactivation of tumor suppressor genes. The purpose of this study was to determine whether hypermethylation of the adenomatous polyposis coli (APC) gene promoter occurs in primary non-small cell lung cancer (NSCLC), and whether hypermethylated APC has any relationship with survival. APC promoter 1A methylation was determined in normal and corresponding tumor tissue from 91 NSCLC patients and in a control group of 10 patients without cancer, using a quantitative fluorogenic real-time PCR (Taqman®) system. APC promoter methylation was detectable in 86 (95%) of 91 tumor samples, but also in 80 (88%) of 91 normal samples of NSCLC patients, and in only two (20%) of 10 normal lung tissues of the control group. The median level of APC promoter methylation was 4.75 in tumor compared to 1.57 in normal lung tissue (P<0.001). Patients with low methylation status showed significantly longer survival than did patients with high methylation status (P=0.041). In a multivariate analysis of prognostic factors, APC methylation was a significant independent prognostic factor (P=0.044), as were pT (P=0.050) and pN (P<0.001) classifications. This investigation shows that APC gene promoter methylation occurs in the majority of primary NSCLCs. High APC promoter methylation is significantly associated with inferior survival, showing promise as a biomarker of biologically aggressive disease in NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW . 1999 Cancer Res. 59: 2302–2306
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW . 2000 Nucleic. Acids. Res. 28: E32
Eguichi K, Kanai K, Hirohasi S . 1997 Cancer Res. 57: 4913–4915
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG . 1999 Cancer Res. 59: 67–70
Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capalla G, Peinando MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG . 2000 Cancer Res. 60: 4366–4371
Ginsberg RJ, Vokes EE, Raben A . 1997 Cancer: Principles in Practice of Oncology Philadelphia: Lippincott-Raven Publishers pp. 858–910
Halpern J . 1982 Biometrics 38: 1017–1023
Heid CA, Stevens J, Livak KJ, Williams PM . 1996 Genome Res. 6: 986–994
Hiltunen MO, Alhonen L, Koistinaho J, Myohanen S, Paakkonen M, Marin S, Kosma VM, Janne J . 1997 Int. J. Cancer 70: 644–648
Jones PA, Laird PW . 1999 Nat. Genet. 2: 163–167
Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Jing Y, Fleisher SA, Abraham JM, Beer DG, Sidransky D, Huss HT, DeMeester TR, Eads C, Laird PW, Ilsen DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ . 2000 J. Natl. Cancer Inst. 92: 1805–1811
Landis SH, Murray T, Bolden A, Wingo PA . 1998 CA Cancer J. Clin. 48: 6–29
Merlo A, Herman JG, Mo L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D . 1995 Nat. Med. 7: 686–692
Miller R, Siegmund D . 1982 Biometrics 38: 1011–1016
Olek A, Oswald J, Walter JA . 1996 Nucleic. Acids. Res. 24: 5064–5066
Pike MC . 1972 J. R. Stat. Soc. Series A. 135: 210–213
Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L . 2000 J. Natl. Cancer Inst. 92: 1511–1516
Tsuchiya T, Tamura G, Satoh K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ . 2000 Oncogene 32: 3642–3646
Acknowledgements
Supported by Hubert Burda Foundation for Cancer Research, Germany (to J Brabender), NCI grant RO1 CA71716 (to PV Danenberg), NCI grants CA85069, CA78843, CA77057, DK47717, and DK53620 (to SJ Meltzer); and by the Medical Research Service, Department of Veterans Affairs (to SJ Meltzer).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brabender, J., Usadel, H., Danenberg, K. et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20, 3528–3532 (2001). https://doi.org/10.1038/sj.onc.1204455
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204455